NADIM II: Phase II Trial of Neoadjuvant Nivolumab + Chemotherapy vs Chemotherapy in Resectable Stage IIIA/B NSCLC

June 3-7, 2022; Chicago, Illinois
This trial confirms benefit of adding neoadjuvant nivolumab to chemotherapy in patients with resectable stage IIIA/B NSCLC, with a pCR rate of 36.8% vs 6.9% with neoadjuvant chemotherapy alone and no impediment to definitive surgery.
Format: Microsoft PowerPoint (.ppt)
File Size: 227 KB
Released: June 10, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Jazz Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation

Related Content

Phase Ib/II CodeBreaK101 study evaluating sotorasib + RMC-4630, an SHP2 inhibitor, in KRAS p.G12C mutant NSCLC, presented at WCLC 2022 reported by Clinical Care Options (CCO)

Released: August 12, 2022

Phase I DeLLphi study evaluating DLL3-targeted agent tarlatamab in relapsed/refractory SCLC, presented at WCLC 2022 reported by Clinical Care Options (CCO)

Released: August 12, 2022

Experts highlight key studies being presented at the upcoming 2022 WCLC annual meeting in this commentary from Clinical Care Options (CCO)

Wade T. Iams, MD, MSCI Heather Wakelee, MD Released: August 5, 2022

Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the management of NTRK and RET-altered malignancies.

Alexander Drilon, MD
Program Director
Thomas Stinchcombe, MD
Program Director
Released: August 4, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings